International journal of geriatric psychiatry
-
Int J Geriatr Psychiatry · Sep 2004
Multicenter Study Clinical Trial Controlled Clinical TrialEfficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long-acting risperidone, the first long-acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ⋯ Long-acting risperidone was associated with significant symptom improvements in stable elderly patients with schizophrenia or schizoaffective disorder. Treatment was well tolerated.